RxDoctor Payments Data

Robert Olson, MD

Family Medicine · Winter Garden, FLNPI 1245203058

Payments from drug & device makers

$7,604in general payments, 2019–2025

Across 364 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$913
  • AbbVie$887
  • Pfizer$591
  • Exact Sciences$470
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$7,593100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,604 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$91,958
Medicare patients
269
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$56,446
EliquisApixaban36$51,349
MounjaroTirzepatide32$42,444
FarxigaDapagliflozin Propanediol17$23,390
JardianceEmpagliflozin17$23,074
XareltoRivaroxaban20$17,081
RybelsusSemaglutide12$13,427
LinzessLinaclotide13$10,649
Atorvastatin Calcium351$3,595
Rosuvastatin Calcium225$3,264
SynthroidLevothyroxine Sodium35$2,841
Levothyroxine Sodium239$2,750
Losartan Potassium254$2,533
Gabapentin88$2,336
Metoprolol Succinate133$1,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,218$69,87345 claims
PfizerEliquis$591$51,34936 claims
Lilly USA, LLCMounjaro$397$42,44432 claims
AstraZenecaFarxiga$1,193$23,39017 claims
Johnson & JohnsonXarelto$253$17,08120 claims
AbbVieLinzess, Synthroid$887$13,49048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →